

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|---|-----------|---|
| (51) International Patent Classification ⁵ : A61F 13/02 | A1 | (11) International Publication Number: WO 90/06736 (43) International Publication Date: 28 June 1990 (28.06.90) |
| (21) International Application Number: PCT/US89/05783 (22) International Filing Date: 15 December 1989 (15.12.89) (30) Priority data: 285,878 16 December 1988 (16.12.88) US (71) Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY [US/US]; Old Queens Building, Somers- et and George Streets, New Brunswick, NJ 08903 (US). (72) Inventors: CHIEN, Yie, W. ; 5 West Lake Court, North Brunswick, NJ 08902 (US). CHIEN, Te-Yen ; 10 Quail Court, Branchburg, NJ 08876 (US). | | (74) Agent: SINN, Leroy, G.; P.O. Box 559, Oldwick, NJ 08858 (US). (81) Designated States: AT (European patent), AU, BE (Euro- pean patent), CH (European patent), DE (European pa- tent), DK, ES (European patent), FI, FR (European pa- tent), GB (European patent), IT (European patent), JP, KR, LU (European patent), NL (European patent), NO, SE (European patent). Published <i>With international search report.</i> |
| (54) Title: TRANSDERMAL ESTROGEN/PROGESTIN DOSAGE UNIT, SYSTEM AND PROCESS (57) Abstract <p>Transdermal estrogen/progestin absorption dosage units have been developed which comprise a backing layer, an adjoining polymer layer is an adhesive layer in which at least minimum effective dose of an estrogen is dissolved or microdispersed. Adhered to the polymer layer is an adhesive layer in which is dissolved and/or microdispersed at least minimum doses of progestin. Presently preferred is use of the natural estrogen, 17-<i>beta</i>-estradiol, or ethinyl estradiol or combinations thereof and of the progestin. The units have biologically acceptable adhesive and polymer layers. The adhesive layer can have dispersed one or more skin permeation enhancing agents. A separating layer can optionally be used in making the dosage units, which separate the adhesive and polymer layers, which permits estrogen transmission from the polymer layer during treatment. Dosage units are provided which transdermally deliver at least minimum daily doses of the estrogen and progestin for multiple days, such as for one week. The invention also provides a process of fertility control and estrogen replacement therapy using the novel dosage units. Also, the invention provides a fertility control system for fertility control using the novel dosage units.</p> | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | |
|----|------------------------------|----|--|----|--------------------------|
| AT | Austria | ES | Spain | MG | Madagascar |
| AU | Australia | FI | Finland | ML | Mali |
| BB | Barbados | FR | France | MR | Mauritania |
| BE | Belgium | GA | Gabon | MW | Malawi |
| BF | Burkina Faso | GB | United Kingdom | NL | Netherlands |
| BG | Bulgaria | HU | Hungary | NO | Norway |
| BJ | Benin | IT | Italy | RO | Romania |
| BR | Brazil | JP | Japan | SD | Sudan |
| CA | Canada | KP | Democratic People's Republic of Korea | SE | Sweden |
| CF | Central African Republic | KR | Republic of Korea | SN | Senegal |
| CG | Congo | LJ | Liechtenstein | SU | Soviet Union |
| CH | Switzerland | LK | Sri Lanka | TD | Chad |
| CM | Cameroon | LU | Luxembourg | TG | Togo |
| DE | Germany, Federal Republic of | MC | Monaco | US | United States of America |
| DK | Denmark | | | | |

5

TRANSDERMAL ESTROGEN/PROGESTIN DOSAGE UNIT,
SYSTEM AND PROCESS

10

CROSS-REFERENCE TO RELATED APPLICATIONS

15

This application is a continuation-in-part of U.S. application Ser. No. 131,462, filed December 16, 1987, which is a continuation-in-part of U.S. application Ser. No. 947,130, filed December 29, 1986.

20

TECHNICAL FIELD

25

30

35

40

45

50

55

This invention relates to a novel transdermal fertility control system and a process for controlling fertility. The system involves transdermal estrogen/progestin absorption dosage units adapted for adhesion to the female subject desiring fertility control or prevention of an unwanted pregnancy. Additionally, the invention relates to a method of controlling fertility by utilizing a transdermal system of applying a series of transdermal estrogen/progestin dosage units having a polymer layer adhered to a backing layer, an adhesive layer, said polymer and adhesive layer having dissolved and/or microdispersed therein estrogen and progestin, respectively, in effective dosage amounts, said polymer and adhesive layers separated by a permselective layer. A biocompatible, effective progestin is selected for use in the dosage units. Preferably, the estrogen used is beta-estradiol, ethinyl estradiol or biocompatible derivatives thereof which have estrogenic activity, preferably

SUBSTITUTE SHEET

5 which are bioconvertible to the estrogen used in the dosage
unit. The dosage units can also be used in estrogenic
10 replacement therapy.

15 BACKGROUND ART

Estrogenic therapies include two main areas, fertility
control and estrogenic replacement.

20 Fertility has been controlled by use of a number of
orally administered hormone products. The products are
ordinarily a combination of an estrogen and a progestin. A
25 synthetic estrogen is ordinarily used as the estrogen compo-
nent since the natural estrogen, 17-beta-estradiol, is al-
most completely destroyed, usually by over 90 percent, when
30 taken orally. It is destroyed to a degree in the digestive
tract before it is absorbed but primarily the destructive
35 metabolism of 17-beta-estradiol occurs during the hepatic
first-pass metabolism. Since such a large amount is
destroyed, in order to provide an effective dosage orally, a
40 large excess must be administered with uncertain effective-
ness and a large amount of unwanted metabolic products.
45 Therefore, a synthetic estrogen such as ethinyl estradiol
normally is orally administered with less than desired re-
50 sults.

The progestin component generally inhibits, as in-
tended, ovulation. Also, in the case of orally administered
55 progestin, a substantial amount of metabolic breakdown

SUBSTITUTE SHEET

5 occurs causing undesired metabolic products with undesired effects.

10 Therefore, in the oral administration of what is commonly referred to as the pill or other orally administered products, considerably overdosing is necessary to obtain a
15 high degree of assurance that the desired fertility control will be obtained.

20 A number of major side effects have reportedly been associated with the administration of oral fertility control preparations, such as thrombophlebitis and thrombosis, pul-
25 monary embolism, coronary thrombosis, myocardial infarction, cerebral thrombosis, cerebral hemorrhage and hypertension. These side effects have been attributed to the estrogen component in the oral preparations. Use of the progestin-
30 only preparations (mini-pill) has been found to eliminate the side effects of estrogen. However, the fertility control is less than that of the combined preparations and the
35 menstrual cycle also becomes more irregular. It has been reported that less incidence of irregular bleeding is observed if the progestin is administered at a more constant
40 rate of delivery. Besides the side effects, the oral fertility control preparations also have the disadvantage of
45 fertility control efficacy depending highly on the degree of patient compliance. The risk of pregnancy is known to increase with each pill missed.

50 An ideal and patient-acceptable fertility control system should provide the following advantages: minimized side
55

SUBSTITUTE SHEET

5

effect, increased ease of administration, rapid termination
of treatment, if needed, and improved patient compliance.
10 In recent years, considerable attention has already been
directed to the development of implantable, intrauterine,
15 intracervical or intravaginal fertility control delivery
systems to provide a prolonged and controlled administration
of steroidal hormones to the body for achieving fertility
20 control; however, none of the delivery systems developed so
far can be considered as ideal and side effect-free.

25 Other fertility control means have been used, such as
topical creams and intravaginal devices, which deliver
combinations of one or more progestins and one or more
30 estrogens, including the naturally-occurring estrogen, 17-
beta-estradiol. However, the undesirable aspects of such
fertility control systems are evident.
35

It is, therefore, highly desired that transdermal sys-
40 tems be provided which permit 1) use of the natural estro-
gen, 17-beta-estradiol, if desired, 2) use of a minimum num-
ber of dosage units for each menstrual cycle, such as use of
45 three successive weekly dosage units, and 3) adherence to
the skin of the subject which would administer sufficiently
high levels of estrogen and progestin hormones to provide
50 high assurance of fertility control without a high amount of
undesired metabolic or chemical degradative products. Devel-
55 opment of a rate-control transdermal drug delivery system,
which is capable of minimizing any individual variability

SUBSTITUTE SHEET

5 and regional differences in skin permeability, is a neces-
sity to attain a predictable blood level of a drug. The
10 transdermal rate-control drug administration is known to
offer several potential advantages for systemic medication:
15 (i) avoidance of the risk and inconvenience of intravenous
therapy and of the variability in absorption and metabolism
associated with oral therapy; (ii) continuity of drug admin-
20 istration, permitting the use of a pharmacologically-active
agent with short biological half-life; (iii) efficacy can be
25 achieved with lower total daily dosage of drug, because of
reduced hepatic first-pass metabolism and continuous drug
input; (iv) less chance of over- or under-dosing, as a
30 result of prolonged, programmed delivery of drug at required
therapeutic rate; (v) provision of a simplified medication
35 regimen; and (vi) ability to rapidly terminate the drug
infusion, if needed, by removal of the drug delivery system
from skin surface. Therefore, a transdermal contraceptive
40 delivery system, which is capable of providing on a fast
effective basis dual-delivery of an estrogen and a progestin
at controlled rates for a specific duration would be an
45 ideal system for achieving fertility regulation in women.

The second main area of estrogenic therapy concerns the
50 need for estradiol replacement therapy. It is caused by
menopause (the cessation of ovarian function), oophorectomy
(loss of one or both ovaries by surgery) or by pituitary
55 failure. Replacement estrogenic therapy is an important
need. Besides the need to alleviate the menopausal symptoms

SUBSTITUTE SHEET

5 caused by estrogenic steroid deficiency, there are addi-
tional contributions of such replacement estrogenic therapy
10 associated with osteoporosis (loss of bone mass) and athero-
sclerosis. It has been found advantageous to administer
15 also an amount of progestin as a part of such estrogenic
replacement therapy. There is clearly a need for improve-
ments in means and methods for estrogenic steroid therapy.
20 Even though it has been found that estradiol itself or
estradiol in the form of certain derivatives such as mono-
25 or diesters (e.g., acetate esters) can be absorbed transder-
mally, it is desired that improved transdermal estradiol and
other estrogenic steroid absorption dosage unit forms and
30 processes of transdermal administration be developed.

35 SUMMARY OF INVENTION

Provided by this invention is a transdermal fertility
control absorption system which permits fertility control by
40 using sequentially three transdermal dosage units which can
easily be applied to a selected skin area.

45 The first dosage unit ordinarily is applied on the
fifth day of a menstrual cycle. The dosage unit is replaced
by the second dosage unit after 7 days and the second is
50 replaced by a third dosage unit at the end of another 7
days. The third dosage unit is removed at the end of 7
55 days, which preferably can be replaced by a fourth placebo
dosage unit. Then, at the beginning of the next menstrual

5 cycle, another sequential course of 3 fertility control
dosage units and the fourth placebo dosage unit is again
10 used, which course is repeated again and again as long as
desired.

15 The transdermal estrogen/progestin dosage units of this
invention comprise:

- 20 a) a backing layer which is substantially impervious
to the estrogen and progestin hormones to be
delivered transdermally and which optionally is
25 breathable, especially if the dosage unit is used
on a long-term basis, such as for several days;
- 30 b) a polymer layer which is in contact with said
backing layer and which has dissolved and/or
microdispersed therein an effective amount of an
35 estrogen, preferably 17-beta-estradiol, ethinyl
estradiol, or a biocompatible derivative thereof
which has estrogenic activity, preferably those
40 derivatives which are bioconvertible to said
estradiols, or a combination thereof, said polymer
layer providing a dosage amount of the estrogen to
45 be delivered transdermally; and
- 50 c) an adhesive layer which can adhere the dosage unit
in intimate contact with the skin of the subject
being treated to permit the hormones to be
55 absorbed transdermally, said adhesive layer being
adhered to the polymer layer and having dissolved

SUBSTITUTE SHEET

5 and/or microdispersed therein an effective dosage
amount of a progestin, selected from the group
10 consisting of norgestrel, levonorgestrel, biocom-
patible derivatives of norgestrel or levonorges-
15 trel which have progestin activity, preferably
biocompatible derivatives which are bioconvertible
to norgestrel or levonorgestrel, said adhesive
20 layer being biocompatible and permitting said
progestin and said estrogen to be transmitted for
25 transdermal absorption, said adhesive layer having
an effective amount of a skin absorption enhancing
agent.

30 Optionally, another layer can be included in the dosage
units between the polymer layer (b) which has present an
35 estrogen and the adhesive layer (c) which has present a
progestin. In this separating layer, it is preferable to
have present little or no estrogen or progestin. The
40 separating layer can be made of selected polymers, for
example, a bioacceptable polyisobutylene which permits the
45 estrogen in layer (b) to be transmitted for transdermal
absorption. Additionally, it is presently preferred that
the separating layer be free of any substantial amount of
50 skin absorption enhancing agent.

The estrogen dissolved or microdispersed in the polymer
55 layer (b) comprises an amount of 17-beta-estradiol, ethinyl
estradiol, biocompatible derivatives thereof which have

SUBSTITUTE SHEET

5 estrogenic activity and which are transdermally absorbed,
said derivatives preferably being bioconvertible to said
10 estradiols, or combinations thereof, which amount of estrogen is effective in providing the role of estrogen in fertility control or in estrogen replacement.

15 The progestin is dissolved or microdispersed in the adhesive layer comprises an amount which will provide the role of progestin in the desired fertility control system or
20 in hormone replacement. The progestin is selected as defined above. Additionally, the adhesive layer has distributed therein an effective amount of transdermal absorption enhancing agent.

30 Preferably, the adhesive layer is divided into two adhesive layers. The first layer (c) has the progestin component above defined dissolved and/or microdispersed
35 therein. The adhesive composition used to make the first adhesive layer has enhancing agent distributed therein. The second adhesive layer is adhered to the first adhesive layer. It also has distributed therein an effective amount
40 of a transdermal absorption enhancing agent.

45 Desirably, the surface of the adhesive layer making contact with the subject being treated has a sufficiently
50 low concentration of transdermal skin permeation enhancing agent and other components to permit good adhesion of the dosage unit to subject treated. The adhesive layer making
55 contact with the skin of the subject can be made in a manner that surface thereof has a lower enhancing agent content to

SUBSTITUTE SHEET

5

provide better adhesion to the subject.

10

Suitably, the dosage units will provide the desired rate of transdermal absorption of the estrogen and progestin components for a period of several days, preferably for one week. Use of week-long transdermal dosage units minimize the possibility of missed administration of a dosage in fertility control.

20

25

The backing layer is made from materials that are substantially impermeable with regard to the hormones of the transdermal dosage unit. It can be made of polymers such as polyethylene, polypropylene, polyurethane, polyvinyl-chloride, polyesters such as poly(ethylene phthalate), and foils such as laminates of polymer films with metallic foils such as aluminum foil. If the dosage units are used on a long term basis, such as for a multiple of days, the backing can have a microporosity to permit passage of sweat and air to minimize any skin hydration.

40

45

50

55

The polymer disc layer is suitably fabricated from biologically acceptable lipophilic or hydrophilic polymers, which will permit the estrogen to be transmitted for transdermal absorption and which provide compatibility and stability for the estrogen. The polymer layer which has the estrogen distributed therein can preferably be made of a suitable polymeric adhesive, such as a suitable polyacrylic or a silicone adhesive in which the estrogen is stable and microdispersible or soluble. The polymer layer can also be

SUBSTITUTE SHEET

5 made using a polymer, such as silicone medical grade elasto-
mers, to fabricate a disc in which the estrogen is microdis-
10 persed. The polymer-estrogen mixture is then formed into a
layer of an appropriate thickness and suitable surface area
and is cured, if desired. The polymer disc layer is then
15 adhered to the backing layer. Care must be taken that the
polymer selected is compatible with the pharmaceutical,
permits its release for transdermal absorption and is free
20 or sufficiently free from any biologically unacceptable
components.

25 Other estrogenic steroid hormones can be used in par-
tial or complete replacement of 17-beta-estradiol or ethinyl
estradiol, for example, biocompatible derivatives thereof,
30 e.g., an ester of 17-beta estradiol which is biologically
compatible and can be effectively absorbed transdermally and
35 at a rate compatible with the desired rate of absorption of
progestin. Also, it is ordinarily desired that such esters
40 are bioconvertible by components of the skin or other por-
tions of the body, such as hydrolytical enzymes (e.g.,
esterase), to 17-beta-estradiol. If the derivative is an
45 ester, the derivative can be selected from mono- or di-
esters since estradiol has hydroxy groups at the 3- and 17-
50 positions, the 3-mono and 17-mono as well as the 3,17-di-
esters can be made by generally known esterification
methods. Some ester derivatives will be absorbed more
55 readily than the basic 17-beta-estradiol. In selection of
ester derivatives, it is ordinarily preferred that the main

SUBSTITUTE SHEET

5

10

15

estrogen hormone used be absorbed at a rate to provide a desirable amount of the estrogen hormone component on a daily basis in a system which simultaneously effects transdermal absorption of the progestin hormone in an effective daily dosage amount over a several day period, preferably one week.

20

25

30

Regarding the daily dosages of progestin for fertility control in humans, about 20 to about 1000 mcg, preferably about 50 to about 250 mcg/day if the progestin used is levonorgestrel, are suitable. Regarding estrogen, about 25 to about 100 mcg/day of estrogen based on 17-beta-estradiol are presently believed suitable daily doses for achieving fertility control in humans.

35

40

45

50

55

Finally, the adhesive layer of the dosage unit is assembled with the other layer elements to form the dosage unit. The adhesive layer selected can vary depending on many factors including economic factors such as the type of manufacturing equipment most readily available, the rapidity of absorption desired or other factors. For example, the adhesive layer can be applied directly to the polymer layer. A skin permeation enhancer compound can be incorporated thoroughly in the adhesive polymer which is suitable for adhesion to the skin locus to which the transdermal dosage unit will be applied. The progestin used is also dissolved or microdispersed in the adhesive layer. The adhesive layer can be applied to the polymer layer by coating or by solvent

SUBSTITUTE SHEET

5 casting and/or laminating. The concentration of skin permea-
tion enhancing agent, if employed, can be reduced in the
10 portion of the adhesive layer means coming in contact with
the subject to be treated, especially if less than desired
adhesion is realized in the adhesive layer, by applying the
15 surface portion of the adhesive layer separately, wherein
the adhesive composition has a lower concentration of skin
permeation enhancing agent or progestin or both. The
20 adhesive layer is desirably thin in the micron-range thick-
ness, suitably 5-250 microns in thickness, desirably about
25 10 to 200 microns, and preferably about 20 to 150 microns in
thickness. Also, if desired, an additional adhesive means
30 can be used in the form of a ring or an overlay adhered to
the backing layer which extends beyond the circumference of
the polymer layer.

35 The optional separating layer if employed is applied to
the polymer layer prior to the assembly of the adhesive
40 layer (c) having present progestin. Alternatively, the
separating layer can be applied to the surface of the adhe-
sive layer prior to its assembly into the dosage unit. The
45 separating layer is made of a suitable polyisobutylene.

The absorption rate of one or both of the hormones of
50 the transdermal hormone absorption dosage units of the in-
vention can be increased, such as by having an Enhancing
Factor of at least 1.2, preferably at least 1.3, and more
55 preferably at least about 1.5 or 2.0. Enhancing Factor is
defined as the ratio of normalized permeation rate [in

SUBSTITUTE SHEET

5
10
15
20
25
30
35
40
45
50
55

mcg/cm²/hr] of a dosage unit of this invention with skin permeation enhancer in the adhesive layer/the normalized permeation rate of a corresponding dosage unit without enhancer in the adhesive layer.

The invention also is a process for administering said hormones transdermally by forming hormone-containing dosage units having a polymer layer which has the estrogen dosage dissolved or microdispersed therein, to which polymer layer is adhered a backing layer, said dosage unit having assembled therewith an adhesive layer which transports the estrogen and progestin and contains the progestin and transdermal absorption enhancing agent; applying the dosage unit in intimate contact with the skin of the subject treated; and administering the hormones transdermally to said subject to achieve fertility control or estrogen replacement.

Additionally, provided by this invention is a novel fertility control absorption system in which a series of three dosage units are provided to be applied in treatment for three successive weeks as described above, in which the first, second and third week dosage units provide differing progestin/estrogen skin permeation dosage rate ratios.

The first dosage unit applied ordinarily on the fifth day of the menstrual cycle delivers about equal dosage amounts of progestin and estrogen, based on levonorgestrel equivalence in the case of progestin and 17-beta-estradiol equivalence in the case of estrogen. In the first dosage

SUBSTITUTE SHEET

5 unit as well as in the second and third dosage units,
sufficient 17-beta-estradiol will suitably be incorporated
10 to deliver transdermally an effective amount in the range of
from about 30 to about 100 mcg per day, desirably about 50
mcg per day.

15 The dosage unit for the second treatment week delivers
about a 50 percent increase in the relative amount of pro-
gestin, i.e., a progestin/estrogen dosage rate ratio of
20 about 1.5:1.0, suitably a rate ratio of from about 1.25:1.0
to about 1.75:1.0, based on the same progestin and estrogen
25 equivalence expressed above regarding the first week dosage
unit.

30 The dosage unit for the third treatment week delivers
about a 150 percent increase in the relative amount of
progestin as compared to the dosage unit for first week or a
35 dosage rate ratio of about 2.5:1.0, suitably a rate ratio of
about 2.0:1.0 to about 3.0:1.0, based on the same equiva-
40 lence expressed above regarding the first week dosage unit.
It will be understood by those skilled in the art that the
ratio can be adjusted depending upon a number of factors,
45 for example, the ratio can be varied to an effective range
in the dosage rate ratio range of about 0.5:1 to about 5:1,
50 based on the same progestin and estrogen equivalence factors
expressed above regarding the first week dosage unit.

55

SUBSTITUTE SHEET

5

BRIEF DESCRIPTION OF THE DRAWINGS

10

15

FIG. 1 is a cross section of a dosage unit of the invention having six layers including two separated drug reservoir layers having estrogen (layer showing drug presence using dots) and progestin (layer showing drug presence as flattened ovals), respectively.

20

25

FIG. 2 is a cross section of a dosage unit of the invention having five layers: (1) release layer, (2) levonorgestrel/enhancer layer, (3) Oppanol B80, (4) estradiol in acrylic adhesive and (5) backing layer.

30

FIG. 3 is a graph showing effect of varying the thickness of the layer separating the progestin- and estrogen-containing layers on the respective skin permeation rates across young female cadaver skin.

35

40

FIG. 4 is a graph showing the effect of diffusional resistance ($10^4/KD$) of the layer separating the progestin (levonorgestrel)- and estrogen (estradiol)-containing layers on the respective skin permeation rates.

45

FIG. 5 is a graph showing the effect of the thickness of the layer separating the progestin (levonorgestrel)- and estrogen (estradiol)-containing layers on the drug absorption permeation rate ratios thereof.

50

55

FIG. 6 is a graph showing the effect of storage at specified temperatures for specific duration on the skin permeation rates of contained progestin (levonorgestrel) from the dosage units.

SUBSTITUTE SHEET

5

10

FIG. 7 is a graph showing the effect of storage at specified temperatures for specific duration on the skin permeation rates of estrogen (estradiol) from the dosage units.

15

FIG. 8 is a graph showing the effect of storage at specified temperatures for specific duration on chemical stability of progestin (levonorgestrel) in the dosage units.

20

25

FIG. 9 is a graph showing the effect of storage at specified temperatures for specific duration on the chemical stability of contained estrogen (estradiol) from the dosage units.

30

FIG. 10 is a graph showing the effect of the loading dose of estradiol in the dosage units on the skin permeation rate of estradiol.

35

FIG. 11 is a graph showing the effect of concentration of enhancer in the dosage units on the skin permeation rate of levonorgestrel.

40

45

FIG. 12 is a graph showing the profiles of the absorption of the progestin (levonorgestrel) and the estrogen (estradiol) over a period of time.

50

FIG. 13 is a graph showing the effect of the diffusional resistance [$10^2/\text{KD}$] of the separating layer on absorption rate ratio of levonorgestrel and estradiol.

55

FIG. 14A and 14B are graphs showing the results of varying the CH_2 group number of alkyl chain length in two classes of transdermal skin permeation enhancing agents

SUBSTITUTE SHEET

5 (alkanoic acids and alkanols) on skin permeation rate of
levonorgestrel contained in the dosage units.

10 FIG. 15 is a graph of a series of curves showing
cumulative (Q) transdermal absorption of ethinyl estradiol
15 from "AD TYPE TDDS" (adhesive type transdermal drug delivery
system) through hairless mouse skin using seven different
formulas.

20 FIG. 16 is a graph of a series of curves showing
cumulative (Q) transdermal absorption of norethindrone from
adhesive type transdermal drug delivery system through
25 hairless mouse skin using seven different formulas.

FIG. 17 is a graph showing transdermal absorption rates
30 of ethinyl estradiol across human cadaver skin depending
upon transdermal absorption enhancer concentration.

35 FIG. 18 is a graph showing transdermal absorption rates
of norethindrone across human cadaver skin depending upon
transdermal absorption enhancer concentration.

40 FIG. 19 is a graph showing the effect of loading dose
of norethindrone through human cadaver skin from dosage
units of the invention in which both the polymer layer and
45 adhesive layer are made from adhesive polymer.

50
55
SUBSTITUTE SHEET

5

DETAILED DESCRIPTION OF THE INVENTION AND THE PREFERRED EMBODIMENTS

10

15

20

25

30

35

40

45

50

55

The backing layer can be made of any suitable material which is impermeable to the hormones of the polymer layer. The backing layer serves as a protective cover for the polymer layer and provides also a support function. The backing can be formed so that it has essentially the same size as the hormone-containing polymer layer or it can be of larger dimension so that it can extend beyond the side of the disc layer or overlay the side or sides of the hormone-containing disc layer and then can extend outwardly in a manner that the surface of the extension of the backing layer can be the base for an additional adhesive means. For long-term applications, e.g., for seven days, it is desirable to use microporous and/or breathable backing laminates, so hydration or maceration of the skin can be minimized. The adhesive means holds the dosage unit in intimate contact with the skin of the subject treated. Examples of materials suitable for making the backing layer are films of high and low density polyethylene, polypropylene, polyurethane, polyvinylchloride, polyesters such as poly(ethylene phthalate), metal foils, metal foil laminates of such suitable polymer films, and the like. Preferably, the materials used for the backing layer are laminates of such polymer films with a metal foil such as aluminum foil. In such laminates, a polymer film of the laminate will usually be in contact with the polymer layer. The backing


SUBSTITUTE SHEET

layer can be any appropriate thickness which will provide the desired protective and support functions. A suitable thickness will be from about 10 to about 200 microns. Desirably, the thickness will be from about 20 to about 150 microns, and preferably be from about 30 to about 100 microns.


The polymer layer can also be made from pressure sensitive adhesive polymers, such as polyacrylic, silicone or other suitable polymer adhesives. The polymer layer can also be made, for example, from silicone elastomers of the general polydimethylsiloxane structure, such as silicone polymers of the following general formula:

A. COMPOSITION


1) POLYMER



2) CROSSLINKER



B. CURING CHEMISTRY



SUBSTITUTE SHEET

5 wherein Me is methyl and wherein x and y represent
independent numbers sufficiently large to provide the
10 desired properties in the polymer layer.


The silicone polymers selected preferably are cross-
linkable at moderate temperatures, such as room temperature,
15 using cross-linking catalysts which are biologically accept-
able in the final polymer layer and which are compatible
20 with the hormone components to be used in making the polymer
dosage forms. Various suitable crosslinking agents can be
used in crosslinking the above polymer, such as the silicone
25 elastomer containing reactive H atoms, if the base polymer
has vinyl groups such as terminal $-\text{CH}=\text{CH}_2$ groups. A
30 platinum catalyst can be used for such crosslinking
reaction. If a silicone polymer component has hydroxy
groups, it can be crosslinked with a tetrapropoxy silane
35 using a catalyst such as a suitable tin catalyst. Some
suitable silicone polymers are cross-linkable copolymers
40 having dimethyl and methylvinyl siloxane units, which can be
cross-linked as by using a suitable peroxide catalyst.
Other cross-linking sites can be present in the polysiloxane
45 elastomers used. Suitable silicone medical-grade polymers
are sold under the designations MDX-4-4210, Silastic 382,
50 Q7-4635, Q7-4650, Q7-4665, Q7-4735, Q7-4750, and Q7-4765.

The silicone polymers selected can also have a "block"
or "graft" structure or both. By "block" structure is meant
55 that the polymer can have a section or block of the polymer
chain structure of the polymer which can have a repeating

SUBSTITUTE SHEET

unit of one type, such as dimethylsiloxane, and then have a succeeding block made up of repeating units of another type, such as methylvinylsiloxane, diphenylsiloxane, diisopropyl siloxane units or other siloxane or silane units or even of monomer units of a compatible non-siloxane or non-silane type. The blocks can vary in length and be repeated as desired. For example, if the blocks are represented as "A" and "B", respectively, the block copolymer can be A-B or A-B-A or A-B-A-B, etc. The "graft" structure simply means that to the main polymer chain, one or more polymer chains are attached. Those grafted chains can have the same polymer units as those of the main chain or can be different, as described above in connection with "block" copolymers. Also, the polymer used can be of a different type wherein copolymerizable monomers are placed together in a polymerization reactor so the main chain can have a certain population of each of the monomeric units.

The following are examples of block copolymers of the type which can be utilized in this invention.




SUBSTITUTE SHEET

5

"B" Block


10



15

or

20



25

30

wherein x, y and z represent the number of repeating units sufficient to provide the desired property in the polymer, such as from about 10 to about 5000.

35

40

45

50

Generally, those polymers used to form the biologically acceptable polymer layer are those capable of forming thin walls or coatings through which hormones can pass at a controlled rate. Suitable polymers are biologically and pharmaceutically compatible, non-allergenic and insoluble in and compatible with body fluids or tissues with which the device is contacted. The use of soluble polymers is to be avoided since dissolution or erosion of the matrix would affect the release rate of the hormones as well as the capability of the dosage unit to remain in place for convenience of removal.

55

Exemplary materials for fabricating the biologically acceptable polymer layer include polyethylene, polypropylene, polyurethane, ethylene/propylene copolymers, ethy-


SUBSTITUTE SHEET

5
lene/ethylacrylate copolymers, ethylene/vinyl acetate co-
10 polymers, silicone elastomers, especially the medical-grade
polydimethylsiloxanes, neoprene rubber, polyisobutylene,
polyacrylate, chlorinated polyethylene, polyvinyl chloride,
15 vinyl chloride-vinyl acetate copolymer, polymethacrylate
polymer (hydrogel), polyvinylidene chloride, poly(ethylene
terephthalate), butyl rubber, epichlorohydrin rubbers, ethy-
20 lene-vinyl alcohol copolymer, ethylene-vinyloxyethanol co-
polymer; silicone copolymers, for example, polysiloxane-
25 polycarbonate copolymers, polysiloxane-polyethylene oxide
copolymers, polysiloxane-polymethacrylate copolymers, poly-
siloxane-alkylene copolymers (e.g., polysiloxane-ethylene
30 copolymers), polysiloxane-alkylenesilane copolymers (e.g.,
polysiloxane-ethylenesilane copolymers), and the like; cel-
35 lulose polymers, for example methyl or ethyl cellulose,
hydroxypropyl methyl cellulose, and cellulose esters; poly-
carbonates; polytetrafluoroethylene; and the like. For best
40 results, the biologically acceptable polymer layer should be
selected from polymers with glass transition temperatures
45 below room temperature. The polymer may, but need not
necessarily, have a degree of crystallinity at room tempera-
50 ture. Cross-linking monomeric units or sites can be incor-
porated into such polymers. For example, cross-linking
monomers can be incorporated into polyacrylate polymers,
55 which provide sites for cross-linking the polymer layer
after microdispersing the hormones into the polymer. Known

SUBSTITUTE SHEET

cross-linking monomers for polyacrylate polymers include polymethacrylic esters of polyols such as butylene diacrylate and dimethacrylate, trimethylol propane trimethacrylate and the like. Other monomers which provide such sites include allyl acrylate, allyl methacrylate, diallyl maleate and the like.

The adhesive and polymer layers are suitably made using a silicone based pressure sensitive adhesive, such as a (polydimethylsiloxane-silicate resin) copolymer adhesive depicted by the following formula:




wherein Me is methyl and R is $-\text{Si}(\text{CH}_3)_3$ and x and y represent independent numbers of repeating units sufficient to provide the desired properties in the adhesive polymer and other polymer layers.

For example, adhesive polymer products or amine-resistant adhesive polymer products sold by Dow Corning, such as the ones sold under the designations of DC-355, Bio-PSA and X7-2920 medical adhesives, are suitable for use in making the adhesive layer. The adhesive polymer must be biologi-


SUBSTITUTE SHEET

5 cally acceptable and compatible with the hormones and skin
permeation enhancer, if used. Certain polyacrylic adhesive
10 polymers (in the form of an alkyl ester, amide, free acid,
or the like) or polyisobutylene adhesive polymers can also
be used with some hormones. Illustrative of suitable
15 adhesive polymers for use in making the polymer layer are
shown by the following formulas:

20 Polyisobutylene Adhesive



Polyacrylic Adhesive



wherein x represents the number of repeating units suffi-
50 cient to provide the desired properties in the adhesive
polymer and R is H or lower alkyl including ethyl, butyl and
2-ethylhexyl.

55

SUBSTITUTE SHEET

5 Other suitable hypoallergenic pressure-sensitive con-
tact adhesive compositions can also be used. A preferred
10 adhesive layer is pressure-sensitive.

 However, depending upon pharmaceutical compatibility
and other factors, if desired, the adhesive means can extend
15 in the form of a ring attached, for example, to an extended
portion of the backing layer so that the adhesive layer is
adjacent to the sidewall of the hormone-containing disc
20 layer. The width of such adjacent adhesive ring must be
adequate to hold the dosage unit securely to the subject
25 being treated. Ordinarily, a suitable width of such adhe-
sive ring can be about 0.1 to about 1.0 cm, preferably about
0.2 to about 0.8 cm.
30

 The adhesive layer then is finally covered with a
releasable protective film layer which is made from mate-
35 rials which are substantially impermeable to the hormones,
the skin permeation enhancer, if used, and any other compo-
nents of the dosage unit. The polymer materials and metal
40 foil laminates used for the backing layer may also be used
to make the protective layer, provided the layer is made
45 strippable or releasable such as by applying conventional
siliconizing or teflon coating. A suitable releasable mate-
rial for use with silicone polymer adhesive DC-355 and X7-
50 2970 is Scotchpak 1022 material sold by the 3M Company or
Bio-Release Material by Dow Corning.

55 In making the hormone-containing polymer layer, sili-
cone elastomers, such as (polydimethylsiloxane-silicate

SUBSTITUTE SHEET

5 resin) copolymer, polyacrylic adhesive, such as sold under
the designation Duro-Tak, of the formula described above,
10 and other biocompatible adhesive polymers which provide a
stable environment for the hormones and permit their
15 release, can suitably be used. In making hormone-dispersed
dosage units, it has been found suitable to use a dispersing
agent. For example, polyethylene glycol such as
20 polyethylene/water combination. PEG 400 is suitable.
Suitable enhancing agents can also be used as the dispersing
25 agent. Other suitable dispersing agents can also be used
instead so long as they are effective. Depending upon the
hormones and the drug loading desired, a suitable amount of
30 a dispersing agent can be varied from zero to about 20
percent (by weight) or more based on the weight of the
polymer layer. Commonly, the dispersing agent is added
35 together with the hormone into the polymer used in making
the layer. The amount of dispersing agent added is
40 dependent upon the rate of permeation desired, the particu-
lar hormones used, and at times, other factors. The amount
45 of the hormones added depends upon the dosage rate of
hormone and the duration of treatment desired in each
dosage unit and the amount which can be incorporated into
50 the polymer layer to retain suitable structural, diffusion
and other properties in the final polymer layer. It has
55 been found, for example, that the hormones can be satis-
factorily added to 50 parts of the polymer used in making

SUBSTITUTE SHEET

5 the polymer layer, such as polyacrylic adhesive polymer. It
has been found to be preferable to add and disperse the
10 estrogen used in an amount of a selected adhesive polymer.
The mixture of the polymer and hormones is then thoroughly
mixed using a high-torque mixer to form a homogeneous
15 solution or microdispersion of the hormones in the polymer.
After the mixing step, the composition is subjected to
vacuum to remove entrapped air.
20

The deaerated mixture is then applied as by solvent
casting technique, to a suitable substrate, like backing
25 laminate or release liner or other suitable substrate and
heated to a suitable elevated temperature to remove the
solvent. The temperature used should not cause significant
30 degradation of the hormones. The polymer sheet desirably is
about 10 to 400 microns, preferably about 20 to about 300
35 microns, in thickness. The resulting medicated polymer
sheet is removed from the casting machine and another layer
of medicated polymer, containing the same or different
40 hormone, can be further coated on the first medicated
polymer layer formed by direct casting or lamination.

45 The optional separating layer can be made of the
polymeric materials. In making the separating layer, it has
been found suitable to use a bioacceptable polyisobutylene
50 having a suitable molecular weight. For example, the
polyisobutylene use can suitably have a relative molecular
mass M_v (viscosity average) of from about 800,000 to about
55 900,000, such as that of polyisobutylene sold by BASF under

SUBSTITUTE SHEET

5 the designation Oppanol B80, which has a relative molecular
10 mass M_v (viscosity average) value of 850,000. The viscosity
average relative molecular mass is obtained from the
equation: $J_0 = 3.06 \times 10^{-2} \times M^{0.65}$. The viscosity or
15 molecular weight should, generally speaking, be selected
which is sufficiently high to provide a separating layer
20 which is dimensionally stable and which is not excessively
high so as to make fabrication of the separating layer un-
necessarily difficult to provide a functional and pharm-
25 aceutically elegant dosage unit.

The thickness of the separating layer can vary as
30 desired. However, it has been found that a layer thickness
after any solvent removal of about 50 to about 150 microns
to be suitable, with a thickness of about 75 to 125 microns
35 to be preferable. It has been found that a separating layer
having about 100 micron thickness made of a polyisobutylene
40 having a viscosity or molecular weight such as that of
Oppanol B80 to function well, if the estrogen in the polymer
layer is 17-beta-estradiol or ethinyl estradiol.

45 The separating layer should have sufficient thickness
to minimize any migration, especially under prolonged
storage conditions at elevated temperatures, such as 37°C or
50 45°C or greater. Also, the separating layer should be made
of a suitable material and with a sufficient thickness to
55 decelerate the rate of transmission of the estrogen in the
polymer layer, as needed to provide suitably a delivery

SUBSTITUTE SHEET

5 ratio of transdermal absorption from about 0.5:1 to about
30:1, a ratio of about 1 to about 20 being a preferable
10 ratio range.

It has been found that the separating layer can be made
as by dissolving about 10 parts of a suitable polyisobuty-
15 lene, such as Oppanol B80 polyisobutylene in a suitable
solvent, such as a mixture of cyclohexane, hexane and
20 heptane (for example, a 1:1:1 mixture). The mixture is
gently agitated such as by using a suitable rotator.

When the dissolution is substantially completed to pro-
25 vide a clear polyisobutylene solution, the solution can be
used to coat a low adhesion film, such as a polyester film
30 with a fluoropolymer-coated surface such as the material
sold by 3M Company under the designation Scotch-Pak 1022. A
35 R.D. wireless coating bar (such as a #12) can be used for
coating. The resulting coating is dried and is repeated as
necessary to obtain a layer of desired thickness, such as
40 100 microns. The separating layer thus formed can be
assembled into the dosage unit by lamination to the polymer
layer. Alternatively, the separating layer can be applied
45 to the surface of the upper adhesive layer having present
progesterin before being assembled by lamination to the
50 surface of the lower polymer layer having present estrogen.
The finished multilayered polymer layer can then be cut to
form discs with desired shapes and sizes. The polymer layer
55 disc generally should not exceed about 100 sq. cm in area,
suitably about 5 to 100 sq. cm, preferably, about 8 to about

SUBSTITUTE SHEET

5
10 80 sq. cm, generally about 10 to 60 sq. cm being more preferable. The shape of the layer discs can vary; they can be circular, square, rectangular or other desired shape.

15 The hormone-containing polymer layer, generally speaking, may contain some excess of the dispersed hormone over the dosage amount desired to be transdermally absorbed by the subject to be treated. Ordinarily, this excess is
20 small, such as less than 2-fold excess over a weekly projected dose, depending upon the physicochemical properties
25 of the hormones, as well as the nature of the polymer in the polymer layer disc and other factors.

30 The adhesive means, if it contains a skin permeation enhancer, is made as by first blending the enhancer and the progestin and then directly dissolving the blend in the
35 adhesive polymer solution or in a solvent which is compatible with the adhesive polymer solution used to make the adhesive layer containing the skin permeation enhancer.
40 Any suitable amount of solvent can be used as necessary to dissolve the quantity of enhancer and progestin to be
45 admixed with the adhesive polymer solution used. For example, 3 to 10 parts of solvent can be used to dissolve
50 one part of skin permeation enhancer, depending upon the solubility of the enhancer. When using silicone-based
55 adhesive solution, it has been found suitable to use 2 to 20 parts of skin permeation enhancer in 20 to 50 parts of solvent (such as acetone, methyl ethyl ketone,

SUBSTITUTE SHEET

5 trifluorotrichloroethane or other suitable solvent) and add
the solution to 100 parts of the adhesive solution. The
10 enhancer-adhesive combination is thoroughly mixed and a
coating thereof is applied using a film coating machine,
such as referred to in the art as a K-bar coater, directly
15 onto the polymer layer or to a strippable release liner
before laminating onto the polymer layer, as described
above. A suitable release liner is a poly(ethylene
20 phthalate) laminated with aluminum foil or a Teflon-coated
polyester film such as sold under the designation Scotchpak
1022 or Bio-release X7-2741 or X7-2752. The poly(ethylene
25 phthalate) side to which the adhesive-enhancer-progestin
coating is applied, is made strippable by conventional sili-
30 conizing or by other suitable means. The thickness of the
adhesive-enhancer-progestin layer normally is suitably about
35 20 to about 200 microns, preferably about 30 to about 150
microns.

40 The amount of enhancer in the adhesive layer depends in
part on the rapidity at which it is desired that the hor-
mones be absorbed. Generally speaking, about 1 to about 40
45 percent of skin permeation enhancer based on the weight of
the adhesive is suitable, depending upon the enhancer, adhe-
sive polymer, desired adhesiveness and other factors.
50 Desirably, about 5 to about 30 percent of skin permeation
enhancers are used depending upon the above recited factors.
55 The adhesive layer containing the progestin and skin permea-
tion enhancer is transferred to the polymer layer disc

SUBSTITUTE SHEET

5 surfaces by application of lamination technique under a
constant pressure. In order to assure adequate adhesion of
10 the adhesive polymer layer to the skin of the subject
treated, additional adhesive polymer coating having a rela-
15 tively low concentration of enhancer, e.g., 1-20 percent
based on the weight of the adhesive polymer can be further
applied to the surface of progestin-enhancer-polymer layer.
20 The thickness of this coating ordinarily is a minor per-
centage of the thickness of the final adhesive layer, such as
25 20-40 percent of the total adhesive polymer layer. In the
progestin-containing adhesive layer having a suitable higher
concentration of the enhancer is used. Suitable higher
30 concentrations of enhancer are usually 10 to about 30 per-
cent based on the adhesive polymer weight, the solubility
and desired final amount of skin enhancer agent and other
35 factors. The solvent of the respective coatings is removed
by evaporation. The respective coatings can be combined to
40 make the final multi-compartment fertility-control trans-
dermal dosage form by application of lamination technique
45 under a constant pressure or sequential solvent casting
technique.

50 Desirably, the adhesive layer is divided into two
layers, the first layer adhered to the separating layer or
to the polymer layer, if no separating layer is included,
55 will contain the progestin component is dissolved or in
microdispersed form. The first adhesive layer can also have

SUBSTITUTE SHEET

5 an amount of dispersed enhancing agent or can be essentially
free of enhancing agent, depending on rate considerations,
10 the estrogen and progestin used, the polymer and adhesive
used in making the respective layers. The second layer will
15 be made of an adhesive which is the same as used in the
first adhesive layer or can be a different biocompatible
adhesive within the description outlined above and will be
20 free or essentially free of the estrogen or progestin used
in making the respective estrogen and progestin layers. The
25 first and second layers can be made in the manner described
above for the adhesive layer. The layers can be of the
thicknesses described above or can be adjusted to a somewhat
30 lesser thickness.

The multi-layer transdermal hormone dosage units are
excised. The backing layer, if desired, can be shaped
35 around the sides of the dosage unit, including the polymer
layer, if such protection is desired. The resulting hormone
40 polymer dosage unit forms are then placed in appropriate
packaging for storage until they are to be applied in trans-
dermal treatment.

45 At least one estrogen and at least one progestin as
defined above are dissolved and/or microdispersed in the
50 polymer and adhesive layers, respectively. With the con-
trolled release of the hormones at a relatively steady rate
over a prolonged period, typically several days and prefer-
55 ably one week, the subject is provided with the benefit of a
steady infusion of the hormones over a prolonged period.

SUBSTITUTE SHEET

5

10

15

20

25

30

35

40

45

50

55

One of the presently preferred estrogens is 17-beta-estradiol. It is a natural hormone and ordinarily transdermally delivered by an adaptable system of this invention at a desirable daily rate. The 17-beta-estradiol is compatible and can be dissolved or microdispersed in the polymer. The transdermal dosage unit designed for one-week therapy is required to deliver at least about 100 to about 500 mcg (preferably about 125 to about 250 mcg)/day of norgestimate, about 1000 mcg (preferably about 500 to about 1500 mcg)/day of norethindrone or about 25 to about 200 mcg (preferably about 50 to about 150 mcg)/day of levonorgestrel and 20-50 mcg/day of 17-beta-estradiol (or an equivalent effective amount of ethinyl estradiol or another estrogen). In fertility control, that amount of progestin is believed to be necessary to inhibit ovulation and that amount of estrogen is believed needed to maintain normal female physiology and characteristics. Derivatives of 17-beta-estradiol which are biocompatible, capable of being absorbed transdermally and preferably bioconvertible to 17-beta-estradiol can also be used, if the amount of absorption meets the required daily dose of the estrogen component and if the hormone components are compatible. Such derivatives of estradiol can be selected from esters, either mono- or di-esters. The mono-esters can be either 3- or 17- esters. The estradiol esters can be, illustratively speaking, estradiol-3,17-diacetate; estradiol-3-acetate; estradiol-17-acetate; estradiol-3,17-

SUBSTITUTE SHEET

5 divalerate; estradiol-3-valerate; estradiol-17-valerate; 3-
mono, 17-mono and 3,17-dipivalate esters; 3-mono, 17-mono
10 and 3,17-dipropionate esters; corresponding cypionate, heptanoate, benzoate and the like esters; ethinyl estradiol; estrone; and other estrogenic steroids and derivatives thereof which are transdermally absorbable, including benzestrol, chlorotrianisene, dienestrol, mestranol, and the like.

The progestin can be selected from norethindrone, norgestimate, levonorgestrel, (or norgestrel containing both
25 levonorgestrel and its (+) enantiomer), norethynodrel, dydrogesterone, ethynodiol diacetate, hydroxyprogesterone caproate, medroxyprogesterone acetate, norethindrone acetate, norgestrel, progesterone, and the like.

If levonorgestrel is used as the progestin, account
35 must be taken of its high progestin potency on a weight basis. The amount used in the adhesive layer adequate for a daily dose can vary so long as it is effective in combination with the estrogen used to provide the desired fertility control or estrogen replacement. Ordinarily, in fertility
40 control, an effective amount in the range from about 25 to about 200 will be used, preferably about 50 to about 150 per dosage unit. In making an estrogen replacement dosage unit, lower daily dosages are adequate for effective estrogen
45 therapy.

55 It will be suggested to those skilled in the art to use other estrogens or progestins in forming the dosage units of

SUBSTITUTE SHEET

5

10

this invention. Such use of other estrogens and progestins are intended to be within the scope of this invention insofar as use thereof provides satisfactory dosage units within the spirit of this invention.

15

It is further desirable to vary the ratio of progestin/estrogen absorption dosage rate among the first, second and third week dosage units.

20

25

30

35

40

In the first week dosage unit, it is desirable to have a rate of absorption of about equal amounts of progestin and estrogen (ratio of about 1/1), based upon use of levonorgestrel as the progestin and estradiol as the estrogen. The ratio can be varied such as from about 0.75:1 to about 1.25:1 to provide an effective dosage amount. In use of other progestins and estrogen, the amounts used will be adjusted to provide a rate amounts absorbed which are bioequivalent to the respective rate amounts of progestin and estradiol.

45

50

In the second week dosage unit, a progestin/estrogen rate of absorption ratio of about 1.5:1 is, generally speaking, suitable. However, the rate of absorption ratio can be varied such as from 1.25:1 to about 2.5:1, depending upon several factors encountered in treatment.

55

In the third week dosage unit, a rate amount of absorption ratio of about 2.5:1 progestin to estrogen, based again upon use of levonorgestrel and estradiol, is, generally speaking, suitable. The rate ratio can be varied to provide

SUBSTITUTE SHEET

5 the effective dosage amount, for example, from about 2:1 to
about 4:1 or 5:1, depending upon variables encountered in
10 practice, to provide a safe and effective fertility control.
Again, in the use of other progestins and estrogens other
than levonorgestrel and estradiol, adjustments to provide
15 rate amounts bioequivalent to levonorgestrel and estradiol,
respectively, will be made.

20 In the use of synthetic estrogens, it is ordinarily
advised presently to keep daily administration below about
50 mcg per subject.

25 In estrogen replacement therapy, it is ordinarily
advised that estradiol administration can range up to about
30 150 mcg per subject per day.

The skin permeation enhancers which can be used in
35 carrying out this invention can vary. Ones that give pre-
ferred results with the polymer dosage unit form having a
specific hormone can vary. In some instances, the use of
40 permeation enhancer in making a dosage unit will result in
good or even excellent absorption for one hormone, may
result in no or relatively low enhancement when another
45 hormone is used. Use of combinations of two or more of the
skin permeation enhancer compounds frequently result in
50 superior results, such as greater transdermal absorption.


Specific skin permeation enhancers which can be used in
making the polymer dosage forms of this invention include
55 saturated and unsaturated fatty acids and their esters,
alcohols, monoglycerides, acetate, diethanolamides and N, N-

5 dimethylamides, such as oleic acid, propyl oleate, oleyl
10 acetate, propyl myristate, isopropyl myristate, myristyl
alcohol, myristyl N, N-dimethyl amide, stearic acid and
15 stearyl alcohol, stearyl propyl ester, monostearin, and
combinations of them with, for example, 1-dodecylazacyclo-
heptan-2-one sold under the trademark Azone by Nelson
20 Research and Development; decyl methyl sulfoxide, dimethyl
sulfoxide, salicylic acid and derivatives, N,N-diethyl-m-
toluamide, crotamiton, 1-substituted azacycloalkan-2-ones
25 such as disclosed in U.S. Patent 4,316,893 (the 1-substi-
tuent having 0-17 carbon atoms, preferably, 1-11 carbon
atoms), and various other compounds which are biologically
30 compatible and have transdermal permeation enhancement
activity. It has been found that n-decyl alcohol is a pre-
35 ferred enhancing agent. Also, it has been found that capric
acid is a preferred enhancing agent. Modifications will be
suggested to those skilled in the art to the chemical struc-
40 tures represented by n-decyl alcohol or capric acid which do
not detract substantially from their function as preferred
45 enhancing agent. It has been found that about 10 to about
40 percent (W/W) of n-decyl alcohol or capric acid is ordi-
narily a suitable amount. It has been found that about 15
50 to about 30 percent (W/W) in the adhesive layer of these
enhancing agents provide highly satisfactory skin absorption
55 enhancement and satisfactory adhesion. Amounts higher than

SUBSTITUTE SHEET


5 35 or 40 percent (W/W) can interfere with satisfactory adhesion to the subject being treated.

10 It has been found that retinol, biocompatible and effective esters thereof, for example retinyl palmitate, retinoic acid, biocompatible and effective esters thereof,
15 are effective transdermal skin permeation enhancing agents. For example, these compounds are effective as secondary enhancing agents. In illustration, these compounds have
20 been found especially effective in combination with n-decyl alcohols, the compounds are the alcohol, the carboxylic acid, and the biocompatible and effective esters of said
25 acid and of said alcohol formed with a carboxylic acid wherein R represents -OH, -COOH and the biocompatible and effective esters thereof.



Also, alpha-tocopherol is an effective transdermal
50 skin permeation enhancing agent. Alpha-tocopherol has been found to be highly effective, for example, in combination with n-decyl alcohol. Biocompatible and effective compounds
55 of the following formula including alpha-tocopherol are also included as enhancing agents:

SUBSTITUTE SHEET



wherein R is selected from hydrogen or methyl. Also included are the biocompatible and effective carboxylic acid esters of the compounds represented by the formula.

A combination of 20 parts of either alpha-tocopherol, retinol, retinyl palmitate, retinoic acid, dl-alpha-tocopherol, dl-alpha-tocopherol acetate, or combinations thereof together with 100 parts of n-decyl alcohol have been found to be effective enhancing agents in carrying out the invention, such as for example when levonorgestrel or norgesterol or biocompatible derivatives thereof are used as the progestin.

Ethyl alcohol and other short chain alkanols (with 1-4 carbon atoms) which have substantially the same properties and activity as ethyl alcohol do not come within the definition of skin permeation enhancer as used herein.

SUBSTITUTE SHEET

5 The following examples are in illustration of the
invention and are not intended to be limiting.

10 Example 1

 The following ingredients are used in making the estro-
15 gen-containing polymer layer: ethinyl estradiol, 5 parts;
polyacrylic adhesive formulation sold by National Starch and
Chemical Corp. as Duro-Tak 80-1054, 95 parts.

20 The ethinyl estradiol is added to the polyacrylic
adhesive using a high torque mixer (sold by Cole-Parmer
25 Company) at a rate of about 1000 RPM.

 The hormone mixture is applied to the backing layer
formed of polyester/aluminum laminate sold by 3M Company as
30 Scotch-Pak 1005, by using a K-bar coater equipped with a
number 3 bar. The resulting polymer layer is dried in the
35 hood for one hour to remove the solvents. The thickness of
the polymer layer obtained is about 10 microns.

40 To the polymer layer, a 5% (W/W) norethindrone in
polyacrylic adhesive solution is applied using a K-bar coat-
er (with #16 bar). In addition to norethindrone, this
45 coating solution also contains 25% (W/W) of n-decyl alcohol
or an amount of other effective skin permeation enhancers.
The coating is dried at ambient room temperature for 24
50 hours. The dried norethindrone-reservoir adhesive layer has
a dry thickness of about 120 microns.

55

 SUBSTITUTE SHEET

5 The bilayer dosage units are then covered with a trans-
parent low-adhesion release liner (Scotch-Pak 1022/3M). The
10 completed dosage layers are then cut into dosage units
having various shapes and sizes by using a specially-
designed device cutter, such as a 20 cm² rectangular shape.

15 The transdermal absorption of the hormones from the
anti-fertility polymer dosage units of this invention is
20 evaluated by using a skin specimen from a "hairless" mouse
or human cadaver by following the procedure described by
Y.W. Chien, K. Valia and U.B. Doshi in Drug Develop. & Ind.
25 Pharm., 11(7) 1195-1212 (1985).

 Transdermal polymer dosage units are obtained following
30 generally the procedures described above and the results are
evaluated as shown in the following Tables 1-2.

35
40
45
50
55

SUBSTITUTE SHEET

5

TABLE 1

10

Rates of Permeation¹⁾ for Ethinyl Estradiol
and Norethindrone Across Hairless Mouse Skin²⁾

15

20

25

30

35

| Formulation | Enhancer | Permeation Rate (mcg/cm ² /hr. \pm S.D.) | (n = 3) | |
|-------------|----------|--|---------------------------------|-----------------------------|
| | | | Ethinyl Estradiol ³⁾ | Norethindrone ⁴⁾ |
| 1 | none | 0.04 (\pm 0.01) | 0.45 (\pm 0.07) | |
| 2 | IPM | 0.25 (\pm 0.05) | 0.97 (\pm 0.19) | |
| 3 | DMSO | 0.13 (\pm 0.02) | 0.52 (\pm 0.14) | |
| 4 | DeMS | 0.16 (\pm 0.03) | 0.39 (\pm 0.07) | |
| 5 | LA | 0.19 (\pm 0.03) | 0.76 (\pm 0.20) | |
| 6 | OA | 0.26 (\pm 0.04) | 1.21 (\pm 0.22) | |
| 7 | DeA | 0.30 (\pm 0.06) | 2.51 (\pm 0.49) | |
| 8 | CA | 0.25 (\pm 0.04) | 2.04 (\pm 0.30) | |

40

1) 12 samples were taken during 115 hours of study.

2) Seven-week-old female hairless mouse abdominal skin.

3) Loading dose: 30.5 (\pm 1.3) mcg/cm²

45

4) Loading dose: 338.0 (\pm 10.1) mcg/cm²

IPM (isopropyl myristate); DMSO (dimethyl sulfoxide); DeMS

(decyl methyl sulfoxide); LA (lauric acid); OA (oleic acid);

50

DeA (Decyl alcohol); CA (capric acid)

55

SUBSTITUTE SHEET

TABLE 2

Rates of Permeation¹⁾ for Ethinyl Estradiol
and Norethindrone Across Human Cadaver Skin²⁾

| Formulation | Enhancer | Permeation Rate (mcg/cm ² /hr \pm S.D.) | | (n = 3) |
|-------------|----------|---|-----------------------------|---------|
| | | Ethinyl Estradiol ³⁾ | Norethindrone ⁴⁾ | |
| 1 | none | 0.02 (\pm 0.004) | 0.14 (\pm 0.03) | |
| 2 | IPM | 0.09 (\pm 0.02) | 0.39 (\pm 0.07) | |
| 3 | DMSO | 0.04 (\pm 0.01) | 0.17 (\pm 0.03) | |
| 4 | DeMS | 0.05 (\pm 0.01) | 0.12 (\pm 0.02) | |
| 5 | LA | 0.07 (\pm 0.02) | 0.26 (\pm 0.04) | |
| 6 | OA | 0.09 (\pm 0.02) | 0.46 (\pm 0.09) | |
| 7 | DeA | 0.13 (\pm 0.02) | 0.89 (\pm 0.18) | |
| 8 | CA | 0.07 (\pm 0.01) | 0.80 (\pm 0.14) | |

1) 12 samples were taken during 122 hours of study.

2) A 17-year-old black boy's left arterial leg with average thickness of 220 (\pm 26) microns.

3) Loading dose: 30.5 (\pm 1.3) mcg/cm².

4) Loading dose: 338.0 (\pm 10.1) mcg/cm².

SUBSTITUTE SHEET

5

Example 2

10

The formulations of the above Tables are repeated using the following procedure.

15

The following ingredients are used in making the estrogen-containing polymer layer: ethinyl estradiol, 5 parts; polyacrylic adhesive formulation sold by National Starch and Chemical Corp. as Duro-Tak 80-1054, 95 parts.

20

The ethinyl estradiol is added to the polyacrylic adhesive using a high torque mixer (sold by Cole-Parker Company) at a rate of about 1000 RPM.

25

30

The hormone mixture is applied to the backing layer formed of polyester/aluminum laminate sold by 3M Company as Scotch-Pak 1005, by using a K-bar counter equipped with a number 3 bar. The resulting polymer layer is dried in the hood for one hour to remove the solvents. The thickness of the polymer layer obtained is about 10 microns.

35

40

45

50

55

To the polymer layer, a 5% (W/W) norethindrone in polyacrylic adhesive solution is applied on a transparent low-adhesion substrate using a K-bar coater (with #16 bar). In addition to norethindrone, this coating solution also contains up to 50% (W/W) of n-decyl alcohol or capric acid as skin permeation enhancer. The coating is dried in the hood at ambient room temperature for 24 hours. The dried norethindrone-reservoir adhesive layer has a thickness of about 120 microns.

SUBSTITUTE SHEET

5 The norethindrone layer is carefully applied to the
ethinyl estradiol layer by lamination technique. The com-
10 pleted dosage layers are then cut into dosage units having
various shapes and sizes by using a specially-designed
device cutter, such as 20 cm² rectangular shape.

15 Transdermal polymer dosage units obtained have provided
skin permeation rates as shown in Table 3.

20

25

30

35

40

45

50

55

SUBSTITUTE SHEET

TABLE 3

Enhancing Effect of Skin Permeation Enhancer on the Skin
Permeation Rates¹⁾ of Ethinyl Estradiol and Norethindrone
Across Human Cadaver Skin²⁾

| Formulation | Enhancer | Permeation Rate (mcg/cm ² /hr \pm S.D.) | (n = 3) |
|--------------------------------|----------|---|-----------------------------|
| | | Ethinyl Estradiol ³⁾ | Norethindrone ⁴⁾ |
| <u>n-Decyl Alcohol (% w/w)</u> | | | |
| 9 | 0 | 0.13 (\pm 0.02) | 0.10 (\pm 0.02) |
| 10 | 2.5 | 0.15 (\pm 0.03) | 0.09 (\pm 0.02) |
| 11 | 5.0 | 0.36 (\pm 0.06) | 0.17 (\pm 0.03) |
| 12 | 10.0 | 0.48 (\pm 0.07) | 0.25 (\pm 0.04) |
| 13 | 25.0 | 1.28 (\pm 0.19) | 1.24 (\pm 0.18) |
| 14 | 50.0 | 1.06 (\pm 0.18) | 1.45 (\pm 0.21) |
| <u>Capric acid (% w/w)</u> | | | |
| 15 | 1.0 | 0.12 (\pm 0.02) | 0.08 (\pm 0.01) |
| 16 | 2.5 | 0.13 (\pm 0.02) | 0.08 (\pm 0.01) |
| 17 | 5.0 | 0.19 (\pm 0.03) | 0.13 (\pm 0.02) |
| 18 | 10.0 | 0.26 (\pm 0.04) | 0.23 (\pm 0.04) |
| 19 | 25.0 | 0.39 (\pm 0.07) | 0.33 (\pm 0.05) |
| 20 | 50.0 | 0.40 (\pm 0.06) | 0.49 (\pm 0.10) |

1) 13 samples were taken during 168 hours of study period.

2) A white male's arterial trunk with average thickness of 180 ± 20 microns (n = 6) were used.

3) Loading dose: $95.7 (\pm 2.9)$ mcg/cm²

SUBSTITUTE SHEET

5 Example 3

10 Example 1 is repeated except the ethinyl estradiol
loading in the polymer layer is varied from 200 mcg/20 cm²
15 to 1600 mcg/20 cm². The above formulation 13 is used. The
data show that the rate of permeation across human skin
increases as the loading of ethinyl estradiol increases
20 until the loading concentration reaches about 1600 mcg/20
cm², at which point increased loadings according to the data
of the experiment do not provide increased permeability.
This is shown in the chart of FIG. 19.

25 Example 4

30 Examples 1 and 2 are repeated except bioactively equi-
valent amounts of 17-beta-estradiol are used instead of
ethinyl estradiol.

35 Example 5

40 Examples 1 and 2 are repeated except bioactively equi-
valent amounts of norgestimate are used instead of norethin-
drone.

45 Example 6

50 Examples 1 and 2 are repeated except bioactively equi-
valent amounts of 17-beta-estradiol and norgestimate are
used instead of ethinyl estradiol and norethindrone, respec-
tively.

5

Example 7

10

Examples 1, 2, 4, 5 and 6 are repeated using polydimethylsiloxane adhesive instead of the polyacrylic adhesive.

15

Example 8

The following ingredients are used in making a tri-layer transdermal estrogen/progestin dosage unit:

20

25

30

35

40

45

50

55

(I) Ethinyl estradiol, 1 part; polyacrylic adhesive (sold by National Starch and Chemical Corp., as Duro-Tak 80-1054), 99 parts. The ethinyl estradiol is dissolved in the polyacrylic adhesive by gently rotating the container using rotator (Cole-Parmer Company) at low speed (10 rpm) to form a clear solution. This hormone/adhesive mixture is applied by coating to a sheet of polyester/aluminum laminate (sold by 3M Company as Scotch-Pak 1109), on the polyester surface, using a R.D. wireless-coating bar (#8). The resulting polymer layer is dried in the hood for one hour to remove the solvent portion. The thickness of the dried estrogen reservoir polymer adhesive layer obtained is about 40 microns.

(II) Polyisobutylene polymer (sold by BASF, as Oppanol B80), 10 parts; 1:1:1 mixture of cyclohexane/hexane/heptane as solvent system for Oppanol B80, 90 parts. The polyisobutylene polymer is dissolved in the solvent system in a closed container by gently rotating the container using a rotator (Cole-Palmer Company) at low speed (10 rpm) until all the polymer is dissolved and a clear solution is formed.

SUBSTITUTE SHEET

5 This polymer solution is applied to the low-adhesion side of
a substrate (a polyester film with fluoropolymer-coated
10 surface, sold by 3M Company as Scotch-Pak 1022) using R.D.
wireless coating bar (#12). This polymer coating is dried
in the hood for 2 hours. The resulting dried polymer film
15 has a thickness of about 100 microns.

(III) Norethindrone, 5 parts; n-decyl alcohol, 35
20 parts; polyacrylic adhesive (sold by National Starch and
Chemical Corp. as Duro-Tak 80-1054), 60 parts. The
norethindrone is dispersed in n-decyl alcohol by rotating
25 gently the container using a rotator (Cole-Palmer Company)
at low speed (10 rpm) to form a drug suspension. The
polyacrylic adhesive is then added to the suspension and the
30 mixture is rotated gently again using the same rotator at a
speed of 10 rpm until a homogeneous mixture is obtained.
35 The mixture is applied to the low-adhesion side of a sub-
strate (a polyester with fluoropolymer-coated surface, sold
40 by 3M Company as Scotch Pak 1022) using a R.D. wireless
coating bar (#28). This coating layer is dried in the hood
for 24 hours. The thickness of the dried norethindrone/n-
45 decyl alcohol reservoir layer obtained is about 250 microns.

The polyisobutylene product of (II) is laminated onto
50 the product of (I) containing ethinyl estradiol. The layer
of (III) containing norethindrone is then laminated into the
combined laminates (I) and (II), on the surface of layer
55 (II), to form the final product. The final laminated
product is cut into specific size using steel die cutter to

SUBSTITUTE SHEET

5

form the tri-layer transdermal estrogen/progestin dosage unit.

10

15

20

25

30

35

40

45

50

55

Units of 10 sq cm are individually packed in the paper/foil/polyester pouches which are then thermally sealed by a thermal sealer. These sealed pouches are stored in the stability testing cabinets (Gravity Convection Incubator, sold by GCA Corp.) at three different temperatures, room temperature, 37°C and 45°C for up to 26 weeks. During the storage, pouches are randomly sampled at specific intervals, according to the sampling schedule shown in Table 4. The units sealed in the pouches are evaluated for their drug content and skin permeation rate profiles. Drug content in each unit was determined by a solvent extraction procedure followed by a high performance liquid chromatograph (HPLC) of the drugs. The skin permeation rate profiles of drugs released from the unit were determined by a hydrodynamically well-calibrated in-vitro skin permeation cell system. The skin specimen freshly excised from 5-to-7 week old female hairless mouse skin was used as the model skin. The skin permeation study was performed at 37°C using 40% V/V PEG 400 saline solution as receptor solution. The steady-state skin permeation rate of norethindrone and ethinyl estradiol was determined from the slope of a Q vs time plot, where Q is the cumulative amount of drug permeating through the skin at a specific sampling time interval. It was calculated by

SUBSTITUTE SHEET

determining the drug concentration in the receptor solution by the HPLC assay.

Drug content or skin permeation rate of drug determined from the stability samples were plotted, according to storage temperature, against the storage time. A 95% confidence limit, based on the mean value obtained from the week 0 samples, is established to make statistical judgment on the physical and chemical stability of the unit tested. Data point that falls outside the 95% confidence limit lines is considered as either chemically (from drug recovery study) or physically (from skin permeation study) unstable.

The stability data are shown in Tables 5 and 6 and are illustrated in FIGS. and .

TABLE 4

| Temperature (KC) | Sampling Schedule (Weeks) | | | | | | |
|---------------------|---------------------------|---|---|---|---|----|----|
| | 0 | 1 | 2 | 4 | 8 | 12 | 26 |
| Room | X | - | - | X | X | X | X |
| 37 | X | - | X | X | X | X | X |
| 45 | X | X | X | X | X | X | X |

SUBSTITUTE SHEET

TABLE 5

Drug Recovery Data of Stability Samples of Dosage Units of Example 8

Sampling Time (Weeks After Storage)

| Temperature | Ethinyl Estradiol (mcg/10 cm ² ± S.D.) ^{1,2} | | | | | | |
|-------------|--|------------------|------------------|------------------|------------------|------------------|------------------|
| | 0 | 1 | 2 | 4 | 8 | 12 | 26 |
| Room Temp. | 529.7 (32.98) | --- | --- | 514.5 (35.57) | 527.7 (34.99) | 517.6 (27.89) | 511.1 (31.31) |
| 37°C | 552.2 (33.89) | --- | 576.8 (37.22) | 539.5 (36.67) | 531.1 (29.45) | 538.9 (43.41) | 522.1 (29.82) |
| 45°C | 540.4 (33.71) | 530.7 (39.98) | 522.7 (37.11) | 539.6 (29.67) | 513.6 (29.98) | 505.7 (42.11) | 495.2 (34.72) |
| | Norethindrone (mcg/10 cm ² ± S.D.) ^{1,2} | | | | | | |
| | 0 | 1 | 2 | 4 | 8 | 12 | 26 |
| Room Temp. | 14.18 (0.98) | --- | --- | 13.43 (1.06) | 13.11 (1.18) | 14.14 (1.32) | 13.01 (1.24) |
| 37°C | 16.67 (1.09) | --- | 15.57 (1.41) | 15.11 (1.11) | 14.40 (1.61) | 14.11 (1.24) | 13.79 (1.18) |
| 45°C | 15.22 (1.43) | 15.01 (1.14) | 14.77 (1.02) | 14.78 (1.31) | 13.49 (1.29) | 13.29 (1.08) | 13.77 (1.19) |

1) Mean ± Standard Deviation (N = 3)

2) Triplicate sample dosage units solvent extracted at indicated storage times and temperatures and the ethinyl estradiol and norethindrone contents determined using high performance liquid chromatography (HPLC).

56

TABLE 6

Skin Permeation Rate of Stability Samples of Dosage Units of Example 8

Sampling Time (Weeks After Storage)

| Temperature | 0 | 1 | 2 | 4 | 8 | 12 | 26 |
|---|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Ethinyl Estradiol (mcg/10 cm ² hr \pm S.D.) ^{1,2} | | | | | | | |
| Room Temp. | 0.20 (0.034) | --- | --- | 0.26 (0.033) | 0.19 (0.021) | 0.26 (0.033) | 0.22 (0.021) |
| 37°C | 0.25 (0.027) | --- | 0.27 (0.040) | 0.22 (0.018) | 0.29 (0.027) | 0.30 (0.041) | 0.22 (0.031) |
| 45°C | 0.28 (0.041) | 0.25 (0.022) | 0.21 (0.026) | 0.31 (0.039) | 0.22 (0.033) | 0.23 (0.042) | 0.20 (0.031) |
| Norethindrone (mcg/10 cm ² hr \pm S.D.) ^{1,2} | | | | | | | |
| Room Temp. | 2.46 (0.26) | --- | --- | 2.38 (0.31) | 2.09 (0.19) | 2.15 (0.25) | 2.57 (0.35) |
| 37°C | 2.33 (0.31) | --- | 2.46 (0.41) | 2.37 (0.35) | 2.72 (0.41) | 2.44 (0.39) | 2.21 (0.34) |
| 45°C | 2.29 (0.33) | 2.56 (0.37) | 2.33 (0.28) | 2.71 (0.37) | 2.53 (0.37) | 2.56 (0.35) | 2.28 (0.31) |

1) Mean \pm Standard Deviation (N = 3)

2) Permeation rates of triplicate sample dosage units determined using 5-7 week-old female hairless mouse skin in Chien et al. procedure for 146 hours and the rates determined from slope of Q vs permeation time plots.

SUBSTITUTE SHEET

5

TABLE 7

Effect of Thickness of Polyisobutylene Layer (Oppanol B80)
on Permeation Rates Across Human Cadaver Skin

| Formulation Number | Human Cadaver Skin Permeation Rates ^{a,b,c,d} (mcg/sq cm hr \pm S.D.) | |
|-----------------------|---|---------------|
| | Ethinyl Estradiol | Norethindrone |
| 2-0 | 0.22 (0.041) | 1.15 (0.100) |
| 2-1 | 0.24 (0.033) | 1.03 (0.170) |
| 2-2 | 0.20 (0.021) | 1.24 (0.210) |
| 2-3 | 0.16 (0.029) | 0.97 (0.160) |
| 2-4 | 0.16 (0.031) | 1.19 (0.240) |
| 2-5 | 0.14 (0.021) | 1.04 (0.250) |
| 2-6 | 0.09 (0.017) | 1.26 (0.280) |
| 2-7 | 0.06 (0.014) | 1.06 (0.190) |
| 2-8 | 0.04 (0.010) | 1.17 (0.200) |
| 2-9 | 0.02 (0.006) | 1.06 (0.230) |

40

a. 11 samples were taken for each of the triplicate experiments (n = 3) during 146 hours of study.

45

b. 40% PEG 400/saline was used as receptor solution.

c. Anterior trunk of a young caucasian female cadaver skin was used.

50

d. Procedure of Chien et al. used, samples taken at times 0, 2, 4, 8, 12, 24, 48, 72, 96, 120 and 146, and rates determined from slopes of Q vs permeation time plots.

55

SUBSTITUTE SHEET

TABLE 8

Variation of Permeation Rates of Norethindrone
Depending on Content of Enhancer

| Formulation Number | % (W/W) of n-Decyl Alcohol | Norethindrone Skin Permeation Rate ^{1,2} (mcg/sq cm hr \pm S.D.) |
|-----------------------|-------------------------------|---|
| 2-10 | 0 | 0.13 (\pm 0.02) |
| 2-11 | 10 | 0.31 (\pm 0.07) |
| 2-12 | 20 | 0.49 (\pm 0.06) |
| 2-13 | 30 | 0.87 (\pm 0.17) |
| 2-7 | 35 | 1.10 (\pm 0.24) |
| 2-14 | 40 | 1.17 (\pm 0.21) |
| 2-15 | 45 | 1.23 (\pm 0.29) |

1) 11 samples were taken for each of triplicate experiments (n = 3) during 146 hours of study.

2) Procedure of Chien et al. used, samples taken at times 0, 2, 4, 8, 12, 24, 48, 72, 96, 120 and 146, and rates determined from slopes of Q vs permeation time plots.

5

TABLE 9

10

Variation of Permeation Rate Ratios
Depending on Enhancer Contents

15

20

25

30

35

40

45

50

55

| Formulation Number | % (W/W) of n-Decyl Alcohol | Ratio of Permeation Rates Norethindrone/Ethinyl Estradiol |
|-----------------------|-------------------------------|--|
| 2-10 | 0 | 4.19 (\pm 0.41) |
| 2-11 | 10 | 8.38 (\pm 0.77) |
| 2-12 | 20 | 12.56 (\pm 1.49) |
| 2-13 | 30 | 18.13 (\pm 2.33) |
| 2-7 | 35 | 18.33 (\pm 2.74) |
| 2-14 | 40 | 15.39 (\pm 1.96) |
| 2-15 | 45 | 13.98 (\pm 1.87) |

SUBSTITUTE SHEET

TABLE 10

Variation of Permeation Rates of Norethindrone
Depending on Content of Enhancer

| Formulation Number | % (W/W) of Capric Acid | Norethindrone Skin Permeation Rate ^{1,2} (mcg/sq cm hr \pm S.D.) |
|-----------------------|---------------------------|---|
| 2-10 | 0 | 0.13 (\pm 0.02) |
| 2-16 | 10 | 0.41 (\pm 0.07) |
| 2-17 | 20 | 0.66 (\pm 0.11) |
| 2-18 | 30 | 1.16 (\pm 0.19) |
| 2-19 | 35 | 1.48 (\pm 0.24) |
| 2-20 | 40 | 1.59 (\pm 0.34) |
| 2-21 | 45 | 1.84 (\pm 0.15) |

1) 11 samples were taken for each of triplicate experiments.
(n = 3) during 146 hours of study.

2) Procedure of Chien et al. used, samples taken at times
0, 2, 4, 8, 12, 24, 48, 72, 96, 120 and 146, and rates
determined from slopes of Q vs permeation time plots.

SUBSTITUTE SHEET

TABLE 11

Variation of Permeation Ratios
Depending on Enhancer Contents

| Formulation Number | % (W/W) of Capric Acid | Ratio of Permeation Rates Norethindrone/Ethinyl Estradiol |
|-----------------------|---------------------------|--|
| 2-10 | 0 | 4.19 (\pm 0.41) |
| 2-16 | 10 | 12.42 (\pm 1.96) |
| 2-17 | 20 | 14.04 (\pm 2.11) |
| 2-18 | 30 | 15.68 (\pm 1.91) |
| 2-19 | 35 | 15.91 (\pm 1.77) |
| 2-20 | 40 | 12.82 (\pm 2.01) |
| 2-21 | 45 | 12.35 (\pm 1.44) |

SUBSTITUTE SHEET

TABLE 12**Variation of Permeation Rates of Ethinyl Estradiol****Depending on Thickness of Adhesive Layer**

| Formulation Number | Thickness of Adhesive Layer (Microns) | Ethinyl Estradiol Skin Permeation Rate ^{1,2} (mcg/sq cm hr \pm S.D.) |
|-----------------------|---|---|
| 2-22 | 142.8 | 0.079 (\pm 0.009) |
| 2-23 | 178.5 | 0.070 (\pm 0.010) |
| 2-24 | 214.2 | 0.066 (\pm 0.008) |
| 2-7 | 250.0 | 0.060 (\pm 0.011) |
| 2-25 | 285.6 | 0.066 (\pm 0.015) |
| 2-26 | 321.7 | 0.074 (\pm 0.011) |

1) 11 samples were taken for each of triplicate experiments.
(n = 3) during 146 hours of study.

2) Procedure of Chien et al. used, samples taken at times 0,
2, 4, 8, 12, 24, 48, 72, 96, 120 and 146, and rates
determined from slopes of Q vs permeation time plots.

SUBSTITUTE SHEET

5

TABLE 13

10

Variation of Ratios of Permeation Rates
Depending on Thickness of Adhesive Layer

15

20

25

30

| Formulation Number | Thickness of Adhesive Layer (Microns) | Ratio of Permeation Rates Norethindrone/Ethinyl Estradiol |
|-----------------------|---|--|
| 2-22 | 142.8 | 3.92 (\pm 0.52) |
| 2-23 | 178.5 | 8.00 (\pm 1.33) |
| 2-24 | 214.2 | 12.27 (\pm 2.02) |
| 2-7 | 250.0 | 18.33 (\pm 2.34) |
| 2-25 | 285.6 | 18.03 (\pm 2.17) |
| 2-26 | 321.7 | 17.16 (\pm 1.99) |

35

40

45

50

55

The following Tables 14 and 15 show data for dosage units without separating layers in comparison with data shown in Tables 5 and 6 for dosage units with separating layers.

64

TABLE 14
Drug Recovery Data from Stability Samples of Bi-Layer Patch System²⁾

| Temperature | Sampling Time (Weeks After Storage) | | | | | | |
|---|-------------------------------------|------------------|------------------|------------------|------------------|------------------|------------------|
| | 0 | 1 | 2 | 4 | 8 | 12 | 26 |
| Ethinyl Estradiol (mcg/10 cm ² ± S.D.) ¹⁾ | | | | | | | |
| Room Temp. | 566.9 (33.18) | --- | --- | 569.4 (34.44) | 536.8 (33.90) | 552.2 (33.11) | 539.9 (35.56) |
| 37°C | 572.5 (40.26) | --- | 570.0 (34.67) | 545.1 (41.11) | 557.5 (31.22) | 539.9 (33.31) | 533.6 (29.98) |
| 45°C | 559.4 (38.88) | 566.9 (44.76) | 530.5 (39.77) | 527.7 (41.12) | 510.0 (44.17) | 519.8 (36.66) | 507.6 (38.98) |
| Norethindrone (mcg/10 cm ² ± S.D.) ¹⁾ | | | | | | | |
| Room Temp. | 15.52 (0.99) | --- | --- | 14.98 (0.92) | 14.16 (0.79) | 15.78 (1.05) | 16.12 (1.11) |
| 37°C | 16.11 (1.19) | --- | 16.64 (0.84) | 15.52 (0.91) | 14.22 (0.77) | 15.78 (1.17) | 14.02 (0.69) |
| 45°C | 17.72 (1.27) | 17.01 (1.00) | 15.24 (0.92) | 14.96 (1.33) | 14.66 (1.07) | 15.28 (1.26) | 14.06 (0.93) |

- 1) Mean ± Standard Deviation (N = 3).
 2) Triplicate sample dosage units solvent extracted at indicated storage times and temperatures and the ethinyl estradiol and norethindrone contents determined using high performance liquid chromatography (HPLC).

TABLE 15
Skin Permeation Rate from Stability Samples of Bi-Layer Patch System 2)

Sampling Time (Weeks After Storage)

| Temperature | 0 | 1 | 2 | 4 | 8 | 12 | 25 |
|-------------|--|----------------|----------------|----------------|----------------|----------------|----------------|
| | Ethinyl Estradiol (mcg/10 cm ² hr \pm S.D.) ¹⁾ | | | | | | |
| Room Temp. | 0.59 (0.04) | --- | --- | 0.52 (0.06) | 0.55 (0.05) | 0.59 (0.04) | 0.64 (0.08) |
| 37°C | 0.61 (0.08) | --- | 0.63 (0.09) | 0.70 (0.07) | 0.73 (0.11) | 0.66 (0.10) | 0.79 (0.14) |
| 45°C | 0.66 (0.11) | 0.69 (0.13) | 0.76 (0.13) | 0.77 (0.08) | 0.74 (0.09) | 0.77 (0.16) | 0.87 (0.12) |
| | Norethindrone (mcg/10 cm ² hr \pm S.D.) ¹⁾ | | | | | | |
| Room Temp. | 2.51 (0.21) | --- | --- | 2.58 (0.26) | 2.44 (0.31) | 2.31 (0.13) | 2.20 (0.23) |
| 37°C | 2.88 (0.21) | --- | 2.95 (0.20) | 2.39 (0.15) | 2.33 (0.17) | 2.22 (0.12) | 2.07 (0.11) |
| 45°C | 2.74 (0.33) | 2.61 (0.22) | 2.50 (0.16) | 2.31 (0.15) | 1.92 (0.25) | 2.05 (0.31) | 2.01 (0.11) |

1) Mean \pm Standard Deviation (N = 3).

2) Permeation rate of triplicate sample dosage units determined using 5-7 week old female hairless mouse skin in Chien et al. procedure for 146 hours and the rates determined from slope of Q vs. permeation time plots.

SUBSTITUTE SHEET

5

Example 9

10

15

20

25

The procedure of Example 8 is followed to provide other transdermal dosage units of this invention: 1) 17-beta-estradiol in combination with norethindrone or norgestimate, 2) ethinyl estradiol-norgestimate combination, and 3) the other combinations with progestins and estrogens selected from those named above, with the amounts necessary to provide the desired fertility control or estradiol replacement. Also, the above dosage units of this Example and Example 8 are repeated using the other adhesives and polymers named above.

30

Example 10

35

40

45

50

55

Transdermal absorption dosage units are made as shown in FIGS. 1 and 2 by following the formulating and fabricating procedure generally described in Example 8. In making the dosage units shown in FIG. 2, the acrylic adhesive used in making layers 2 and 4, respectively, is defined in Example 8. Layer 2 contains levonorgestrel and layer 4 contains 17-beta-estradiol. Separating layer 3 is made using the polyisobutylene adhesive Oppanol B80 defined in Example 8. Backing layer 5 and release liner layer 1 are made from materials described in Example 8.

The primary and secondary enhancing agents are incorporated into levonorgestrel containing layer 2. The amounts of primary and secondary enhancing agents specified in Table 16 are used in making dosage units.

SUBSTITUTE SHEET

5 Permeation rates (mcg/sq. cm/hr \pm S.D.) are determined
using the in vitro procedure of Y. W. Chien et al. identi-
10 fied in Example 1 using male human cadaver skin. The estro-
gen/progestin ratios shown in Table 16 are calculated from
the absorption rates shown in Table 16.

15 Example 11

The transdermal dosage units used and described in
20 FIGS. 1-14 are made using the formulating and fabricating
procedures described in Example 8. The polymer adhesive
25 materials used in Example 8 are used in making adhesive
layer B, levonorgestrel containing layer C, separating layer
D and 17-beta-estradiol layer E. The materials used in
30 making release liner layer A and backing layer F are
described in Example 8.

35 The amounts and identification of enhancing agents used
in layers B and/or C are described in FIGS. 1-14.

The transdermal absorption rates (mcg/sq. cm/hr \pm S.D.)
40 are calculated from data determined using the in vitro ana-
lytical method defined above and the ratios of estrogen/pro-
45 gestin are calculated from the absorption rates determined.

Example 12

50 Other estrogens and progestins are used in place of
levonorgestrel and 17-beta-estradiol as described and named
above in proper amounts to provide bioequivalent rate of
55 absorption amounts.

SUBSTITUTE SHEET

TABLE 16

| Concentration (%W/W) of Enhancer Primary (n-Decyl Alcohol | Secondary | Adult Male Human Cadaver Skin | | Estradiol/Levonorgestrel Rate/Ratio |
|---|------------------------------------|---|-----------------|--|
| | | Permeation Rate (mcg/sq. cm/hr + S.D.) | Levonorgestrel | |
| 25.0 | 0.0 | 0.19 (0.031)* | 0.080 (0.017)** | 2.4 (0.21)*** |
| 25.0 | 5.0 Retinol | 0.21 (0.040) | 0.141 (0.019) | 1.5 (0.11) |
| 25.0 | 5.0 Retinyl Palmitate | 0.18 (0.030) | 0.176 (0.027) | 1.0 (0.13) |
| 25.0 | 5.0 Retinoic Acid | 0.22 (0.033) | 0.159 (0.024) | 1.4 (0.16) |
| 25.0 | 5.0 dl-alpha-Tocopherol | 0.20 (0.031) | 0.127 (0.021) | 1.6 (0.10) |
| 25.0 | 5.0 dl-alpha-Tocopherol Acetate | 0.18 (0.024) | 0.182 (0.029) | 1.0 (0.07) |

68

*Not statistically significant different from the other 5 formulations with secondary enhancer added. (P > 0.05)

**Addition of secondary enhancer significantly (p < 0.05) increases the permeation rate of levonorgestrel over the formulation containing only primary enhancer.

***Addition of secondary enhancer significantly (p < 0.05) decreases the estradiol/levonorgestrel skin permeation rate ratio over the formulation containing only primary enhancer.

SUBSTITUTE SHEET

5

What is Claimed is:

10

1. A transdermal estrogen/progestin dosage unit comprising:

15

a) a backing layer which is substantially impervious to the estrogen and progestin hormones to be delivered transdermally;

20

b) a polymer layer which is adhered to said backing layer and which has dissolved and/or microdispersed therein an effective dosage amount of one or more effective estrogens absorbable transdermally and are pharmaceutically acceptable, said polymer being bioacceptable, providing a compatible environment for said one or more estrogens and permitting said one or more estrogens to be transmitted for transdermal absorption, and

35

40

c) an adhesive layer in intimate contact with said polymer layer, said adhesive layer having dissolved and/or microdispersed therein an effective dosage amount of one or more effective progestins selected from the group consisting of norgestrel, levonorgestrel, and biocompatible derivatives of norgestrel and levonorgestrel. which are absorbable transdermally and are pharmaceutically acceptable, said adhesive layer being bioacceptable, providing a compatible environment for said one or more progestins, and permitting said one or more progestins and said one or more estrogens

45

50

55

SUBSTITUTE SHEET

5

10

15

20

to be transmitted for transdermal absorption, said adhesive layer having an effective amount of transdermal skin absorption enhancing agent; said hormones being stable in said polymer and adhesive layers and being transdermally absorbed simultaneously to provide at least minimum effective daily doses of said hormones to effect fertility control or estrogen replacement therapy.

25

2. A transdermal dosage unit of Claim 1 which has ethinyl estradiol or 17-beta-estradiol or combinations thereof as said one or more estrogens.

30

35

3. A transdermal dosage unit of Claim 1 which has norgestrel or levonorgestrel or combinations thereof as said one or more progestins.

40

4. A transdermal dosage unit of Claim 1 which has ethinyl estradiol as said estrogen and norgestrel or levonorgestrel as said progestin.

45

50

5. A transdermal dosage unit of Claim 1 which has 17-beta-estradiol as said estrogen and norgestrel or levonorgestrel as said progestin.

55


6. A transdermal dosage unit of Claim 1 in which said adhesive layer or said polymer layer or both layers are made from a polyacrylic adhesive polymer.

SUBSTITUTE SHEET

5

7. A transdermal dosage unit of Claim 6 in which said polyacrylic adhesive polymer has the following formula:

10



15

20

wherein x represents the number of repeating units sufficient to provide the defined properties of said adhesive layer or polymer layer or both layers and R is selected from H or lower alkyl.

25

30

8. A transdermal dosage unit of Claim 1 in which the backing layer is microporous and breathable.

35

9. A transdermal dosage unit of Claim 1 in which said adhesive layer or polymer layer or both layers are made from a silicone adhesive polymer or a polyisobutylene adhesive polymer.

40

45

10. A transdermal dosage unit of Claim 1 in which the Enhancing Factor with regard to said progestin is at least 1.2, 1.3, 1.5 or 2.0.

50

11. A transdermal dosage unit of Claim 1 wherein the skin permeation absorption enhancing agent comprises n-decyl alcohol.

55

SUBSTITUTE SHEET

5 12. A transdermal dosage unit of Claim 1 which effectively
provides at least minimum daily dosage amounts of said
10 estrogen and progestin for about one week, having an
amount of said skin permeation absorption enhancing
15 agent to provide an Enhancing Factor of at least about
1.5 with regard to said progestin.

20 13. A transdermal dosage unit of Claim 1 wherein said
polymer layer having present one or more estrogens and
said adhesive layer having present one or more proges-
25 tins are separated by, but are in respective intimate
contact therewith, a bioacceptable adhesive or polymer
separating layer through which said one or more estro-
30 gens are transmitted for desired transdermal absorp-
tion, said separating layer made using an adhesive or
35 polymer which is free or substantially free of estro-
gen, progestin and enhancing agents.

40 14. A transdermal dosage unit of Claim 13 which has ethinyl
estradiol or 17-beta-estradiol or combinations thereof
as said one or more estrogens and norgestrel or levo-
45 norgestrel or combinations thereof as said one or more
progestins.

50
55
SUBSTITUTE SHEET

- 5 15. A transdermal dosage unit of Claim 13 wherein the
separating layer is made from a bioacceptable adhesive
10 or polymer having a sufficiently high viscosity or
molecular weight to provide a dimensionally stable
separating layer and a substantial reduction in the
15 transmission rate of said one or more estrogens.
- 20 16. A transdermal dosage unit of Claim 15 where the sep-
arating layer is made from a polyisobutylene adhesive.
- 25 17. A transdermal dosage unit of Claim 13 wherein the ratio
of transdermally absorbed progestin to estrogen hor-
mones is in the range of about 0.5/1 to about 0.30/1.
- 30 18. A transdermal dosage unit of Claim 17 wherein the ratio
of transdermally absorbed progestin to estrogen hor-
35 mones is in the range of about 1/1 to about 13/1.
- 40 19. A transdermal dosage unit of Claim 17 wherein the
separating layer is made from polyisobutylene.
- 45 20. A transdermal dosage unit of Claim 18 wherein the
separating layer is made from polyisobutylene having a
relative molecular mass M_v (viscosity average) of from
50 about 800,000 to about 900,000.

55

SUBSTITUTE SHEET

5 21. A transdermal dosage unit of Claim 17 which has ethinyl
estradiol or 17-beta-estradiol or combinations thereof
10 as said one or more estrogens and has norgestrel or
levonorgestrel or combinations thereof as said one or
15 more progestins.

20 22. A transdermal dosage unit of Claim 21 wherein the
adhesive or polymer is a bioacceptable polyacrylic
adhesive.

25 23. A transdermal dosage unit of Claim 22 where the sep-
arating layer has a thickness of from about 75 to about
125 microns and the polyisobutylene has a relative
30 molecular mass M_v (viscosity average) of at least about
800,000.

35 24. A process for controlling fertility by applying to the
skin of a subject desiring said treatment one or more
40 dosage units as defined in Claim 1 to provide effective
daily dosage amounts of said estrogen and progestin for
the appropriate term of about three weeks of the men-
45 strual cycle in successive menstrual cycles.

50 25. A process of Claim 24 wherein the estrogen is ethinyl
estradiol or 17-beta-estradiol or combinations thereof
and the progestin is norgestrel or levonorgestrel or
55 combinations thereof.

SUBSTITUTE SHEET

- 5 26. A process of Claim 24 wherein the dosage units applied
are as defined in Claim 13.
- 10 27. A process of Claim 24 wherein the dosage units applied
are as defined in Claim 17.
- 15 28. A process of Claim 24 wherein the dosage units applied
are as defined in Claim 21.
- 20 29. A process of Claim 24 wherein the dosage units applied
are as defined in Claim 22.
- 25 30. A fertility-control system comprising one or more
series of three transdermal absorption dosage units as
30 defined in Claim 1, each dosage unit of which provides
at least minimum effective daily dosage amounts of
estrogen and progestin for about one week, said dosage
35 units to be applied serially for about one week each,
the first dosage unit to be applied about on the fifth
40 day of the menstrual cycle, the second and third dosage
units to be applied about 7 and about 14 days later,
respectively, said application of said series of three
45 transdermal absorption units to be repeated as desired
to control fertility.
- 50 31. A fertility control system of Claim 30 in which trans-
dermal dosage units as defined in Claim 2 are applied.
- 55 32. A fertility control system of Claim 30 in which trans-
dermal dosage units as defined in Claim 13 are applied.

SUBSTITUTE SHEET

5

33. A fertility control system of Claim 30 in which trans-dermal dosage units as defined in Claim 17 are applied.

10

34. A fertility control system of Claim 30 in which trans-dermal dosage units as defined in Claim 21 are applied.

15

35. A fertility control system of Claim 30 in which trans-dermal dosage units as defined in Claim 22 are applied.

20

36. A fertility control system comprising one or more series of three transdermal dosage units, each dosage unit providing at least minimum effective daily dosage amounts of estrogen and progestin for about one week, said dosage units to be applied serially for about one week each, the first dosage unit to be applied about on the fifth day of the menstrual cycle, the second and third dosage units to be applied about 7 and 14 days thereafter, respectively; said dosage units comprising:

25

30

35

40

a) a backing layer which is substantially impervious to the estrogen and progestin hormones to be delivered transdermally;

45

b) a polymer layer which is adhered to said backing layer and which has dissolved and/or microdispersed therein an effective dosage amount of one or more effective estrogens absorbable transdermally and are pharmaceutically acceptable, said

50

55

SUBSTITUTE SHEET

5 polymer being bioacceptable, providing a compat-
ible environment for said one or more estrogens
10 and permitting said one or more estrogens to be
transmitted for transdermal absorption,
15 c) an adhesive layer having dissolved and/or micro-
dispersed therein an effective dosage amount of
one or more effective progestins, which are
20 absorbable transdermally and are pharmaceutically
acceptable, said adhesive layer being bioaccept-
able, providing a compatible environment for said
25 one or more progestins, and permitting said one or
more progestins and said one or more estrogens to
30 be transmitted for transdermal absorption, said
adhesive layer having an effective amount of
transdermal skin absorption enhancing agent; and
35 d) a separating layer made of a bioacceptable adhe-
sive or polymer located between said polymer and
40 adhesive layers and in intimate contact therewith
through which said one or more estrogens are
transmitted for desired transdermal absorption,
45 said separating layer made using an adhesive or
polymer which is free or substantially free of
50 estrogen, progestin and enhancing agents; said
hormones being stable in said polymer and adhesive
layers and being transdermally absorbed simul-
55 taneously to provide at least minimum effective
daily doses of said hormones to effect fertility

SUBSTITUTE SHEET

5 control or estrogen replacement therapy; said
10 dosage units further characterized as follows:

15 a) first dosage unit having a progestin/estrogen
transdermal absorption rate ratio from about
20 0.75/1 to about 1.27/1 based upon the proges-
tin being levonorgestrel or levonorgestrel
bioequivalent amount transdermally absorbed
of another progestin used as said progestin
and further based upon the estrogen being 17-
25 beta-estradiol or 17-beta-estradiol bio-
equivalent amount transdermally absorbed of
another estrogen used as said estrogen:

30 b) second dosage unit having a progestin/estro-
gen transdermal absorption rate ratio from
35 about 1.25/1 to about 2.5/1 based upon the
progestin being levonorgestrel or levonorges-
40 trel bioequivalent amount transdermally
absorbed of another progestin used as said
progestin and further based upon the estrogen
45 being 17-beta-estradiol or a 17-beta-estra-
diol bioequivalent amount transdermally
absorbed of another estrogen used as said
50 progestin; and

55 c) third dosage unit having a progestin/estrogen
transdermal absorption rate ratio from about
2/1 to about 5/1 based upon the progestin

SUBSTITUTE SHEET

5

being levonorgestrel or levonorgestrel bio-equivalent amount transdermally absorbed of another progestin used as said progestin and further based upon the estrogen being 17-beta-estradiol or a 17-beta-estradiol bio-equivalent amount transdermally absorbed of another estrogen used as said progestin.

10

15

20

37. A fertility control system of Claim 36 wherein the progestin is levonorgestrel and the estrogen is 17-beta-estradiol.

25

30

38. A process of estrogen replacement therapy by applying successively to the skin of a subject needing said therapy, dosage units as described in Claim 1 which provide effective dosages respectively of one or more estrogens and one or more progestins for said replacement therapy.

35

40

45

50


55

SUBSTITUTE SHEET

1/19


FIG. 1

Multicompartment-type
Transdermal Drug Delivery System
(m-TDD System)

**SUBSTITUTE SHEET**

2/19


FIG. 2



SUBSTITUTE SHEET

3/19


FIG. 3



SUBSTITUTE SHEET

4/19


FIG. 4



SUBSTITUTE SHEET

5/19


FIG. 5



SUBSTITUTE SHEET

6/19


FIG. 6



SUBSTITUTE SHEET

7/19


FIG. 7



SUBSTITUTE SHEET

8/19


FIG. 8



SUBSTITUTE SHEET


9/19

FIG. 9



10/19


FIG. 10



SUBSTITUTE SHEET


11/19

FIG. 11




12/19

FIG. 12



13/19

FIG. 13

**SUBSTITUTE SHEET**

14A&B/19

Alkanols




FIG. 14B

Alkanoic Acids





FIG. 14A

SUBSTITUTE SHEET

15/19


FIG. 15



SUBSTITUTE SHEET

16/19


FIG. 16



SUBSTITUTE SHEET

17/19


FIG. 17



SUBSTITUTE SHEET

18/19

FIG. 18




SUBSTITUTE SHEET

19/19

FIG. 19

PERMEATION RATE (MCG/CM² HR + S.D.) N = 3



SUBSTITUTE SHEET

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US89/05783

| | | |
|--|--|-------------------------------------|
| I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶ | | |
| According to International Patent Classification (IPC) or to both National Classification and IPC | | |
| IPC(5) A61F 13/02 | | |
| US. CL. 424/448 | | |
| II. FIELDS SEARCHED | | |
| Minimum Documentation Searched ⁷ | | |
| Classification System | Classification Symbols | |
| U.S. | 424/448, 449 | |
| Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸ | | |
| III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹ | | |
| Category ¹⁰ | Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹² | Relevant to Claim No. ¹³ |
| P,X | US, A 4,818,540 (CHIEN ET AL.) 04 APRIL 1989 | 1-38 |
| <p>¹⁰ Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p> | | |
| IV. CERTIFICATION | | |
| Date of the Actual Completion of the International Search | Date of Mailing of this International Search Report | |
| 13 FEBRUARY 1990 | 05 MAR 1990 | |
| International Searching Authority | Signature of Authorized Officer | |
| ISA/US | LEON R. HORNE <i>Leon R. Horne</i> | |

THIS PAGE BLANK (USPTO)